Aravive, Inc. (NASDAQ:ARAV) Sees Significant Growth in Short Interest

Aravive, Inc. (NASDAQ:ARAV) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 4,480,000 shares, an increase of 21.4% from the August 15th total of 3,690,000 shares. Based on an average trading volume of 6,470,000 shares, the short-interest ratio is presently 0.7 days.

Aravive Trading Up 13.3 %

ARAV stock opened at $0.16 on Friday. Aravive has a 52 week low of $0.11 and a 52 week high of $2.46. The company has a market capitalization of $11.77 million, a price-to-earnings ratio of -0.09 and a beta of 2.41. The firm’s 50-day moving average is $0.66 and its two-hundred day moving average is $1.34.

Aravive (NASDAQ:ARAV) last released its earnings results on Monday, August 21st. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.18. Aravive had a negative net margin of 834.54% and a negative return on equity of 1,865.78%. The business had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. On average, equities research analysts predict that Aravive will post -0.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. William Blair lowered shares of Aravive from an “outperform” rating to a “market perform” rating in a report on Thursday, August 3rd. HC Wainwright lowered shares of Aravive from a “buy” rating to a “neutral” rating in a report on Thursday, August 3rd. Cantor Fitzgerald downgraded shares of Aravive from an “overweight” rating to a “neutral” rating in a research report on Tuesday, August 22nd. Finally, BTIG Research downgraded shares of Aravive from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Aravive has a consensus rating of “Hold” and an average target price of $10.17.

Institutional Trading of Aravive

Hedge funds and other institutional investors have recently made changes to their positions in the business. Artal Group S.A. increased its position in shares of Aravive by 248.7% in the fourth quarter. Artal Group S.A. now owns 4,572,515 shares of the company’s stock worth $6,036,000 after acquiring an additional 3,261,224 shares in the last quarter. Renaissance Technologies LLC grew its position in Aravive by 35.0% during the second quarter. Renaissance Technologies LLC now owns 374,945 shares of the company’s stock valued at $370,000 after purchasing an additional 97,116 shares in the last quarter. BlackRock Inc. lifted its stake in Aravive by 53.8% in the second quarter. BlackRock Inc. now owns 320,897 shares of the company’s stock valued at $404,000 after acquiring an additional 112,269 shares during the last quarter. Geode Capital Management LLC lifted its stake in Aravive by 41.3% in the second quarter. Geode Capital Management LLC now owns 304,059 shares of the company’s stock valued at $383,000 after acquiring an additional 88,841 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in Aravive in the first quarter valued at approximately $401,000. 28.48% of the stock is currently owned by institutional investors.

About Aravive

Aravive, Inc, a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma.